Shares of Praxis Precision Medicines (NASDAQ: PRAX) soared over 13% after receiving a Breakthrough Therapy Designation for its experimental tremor treatment. Praxis focuses on genetic insights for neurological disorders and plans to submit a New Drug Application for ulixacaltamide in early 2026. Approximately 7 million people in the U.S. have essential tremor, with limited treatment options available. Before investing in Praxis, consider that it was not included in the Motley Fool’s list of the 10 best stocks to buy right now, which have historically produced significant returns for investors.

Read more at Nasdaq: Why Praxis Precision Medicines Stock Popped Today